BRBR Deadline: BRBR Investors Have Opportunity to Lead BellRing Brands, Inc. Securities Fraud Lawsuit [Accessibility Statement] Skip NavigationNEW YORK, Feb. 27, 2026 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bellring Brands, Inc. (NYSE: BRBR) between November 19, 2024 and August 4, 2025, both dates inclusive (the "Class Period"), of the important March 23, 2026 lead plaintiff deadline.So what: If you purchased BellRing securities during the C ...

The U.S. stock market faced a bruising sell-off on Friday, February 27th, 2026, as a combination of hotter-than-expected inflation data, escalating geopolitical tensions in the Middle East, and fresh anxieties regarding artificial intelligence (AI) disruption hammered investor sentiment. The session concluded a turbulent month for Wall Street, with major indexes posting significant losses as the "higher-for-longer" interest rate narrative regained momentum.Major Market Indexes PerformanceThe Dow Jones Indus ...

Core Insights - The article discusses the current market trends and potential investment opportunities within specific sectors, emphasizing the importance of thorough analysis before making investment decisions [1][2][3] Group 1: Market Trends - Recent market fluctuations have led to increased volatility, prompting investors to reassess their strategies and focus on sectors that show resilience [1] - Certain industries, particularly technology and healthcare, are highlighted as having strong growth potential due to ongoing innovation and demand [2] Group 2: Investment Opportunities - The analysis identifies key companies within the technology sector that are poised for growth, driven by advancements in artificial intelligence and cloud computing [1] - In the healthcare sector, companies involved in biotechnology and telehealth are noted for their potential to capitalize on changing consumer behaviors and regulatory support [2] Group 3: Risk Factors - The article mentions that geopolitical tensions and economic uncertainties could impact market performance, necessitating a cautious approach to investment [1] - Investors are advised to remain vigilant regarding changes in interest rates and inflation, which could affect overall market conditions [2]

Cogent Biosciences Inc. (NASDAQ:COGT) is one of the 15 stocks with the biggest hedge fund momentum, after gaining 25 hedge fund holders during the fourth quarter of 2025. On February 18, Piper Sandler analysts raised their price target on Cogent Biosciences Inc. (NASDAQ:COGT) t0 $52 from $39. According to these analysts, who maintained an Overweight rating on Cogent Biosciences Inc. (NASDAQ:COGT), their $13 increase on the price target is justified by the company’s shift toward regulatory approvals and com ...

Lumentum Holdings Inc. (NASDAQ:LITE) is one of 15 stocks with the biggest hedge fund momentum, after gaining 26 hedge fund holders during the fourth quarter of 2025. On February 23, Morgan Stanley increased the price target on Lumentum Holdings Inc. (NASDAQ:LITE) to $520 from $420, while retaining the stock’s Equal Weight rating, citing the increasing speed of investment in AI data centers. According to Morgan Stanley analysts, optical markets are set to grow to more than $65 billion by 2028 from about $ ...

Taiwan Semiconductor Manufacturing Co. Ltd. (NYSE:TSM) is one of 15 stocks with the biggest hedge fund momentum, after gaining 27 hedge fund holders during the fourth quarter of 2025. On February 24, Apple said that it is on track to purchase more than 100 million advanced chips produced by Taiwan Semiconductor Manufacturing Co. Ltd. (NYSE:TSM) at its Arizona facility, marking a significant increase in orders from 2025. The iPhone maker said that it sourced more than 20 billion U.S.-made chips from 24 fact ...

NVIDIA Corp. (NASDAQ:NVDA) is one of 15 stocks with the biggest hedge fund momentum, after gaining 27 hedge fund holders during the fourth quarter of 2025. On February 25, NVIDIA Corp. (NASDAQ:NVDA) reported record revenue for its fourth quarter ended January 25, 2026, of $68.1 billion, up 20% from the previous quarter and up 73% from a year ago. For fiscal 2026, revenue was $215.9 billion, up 65% from a year ago. For the quarter, GAAP and non-GAAP earnings per diluted share were $1.76 and $1.62, respect ...

Core Viewpoint - AllianceBernstein Global High Income Fund, Inc. reported a decrease in total net assets and net investment income for the third quarter ended December 31, 2025, compared to the previous quarter and the same period last year [1]. Financial Performance - Total net assets as of December 31, 2025, were $985,227,126, down from $993,104,684 on September 30, 2025, and up from $978,431,163 on December 31, 2024 [1]. - The net asset value (NAV) per share was $11.43, a decrease from $11.52 in the previous quarter and an increase from $11.35 a year ago [1]. - Total net investment income for the period was $15,059,136, or $0.17 per share, compared to $31,772,437 ($0.20 per share) in the second quarter and $16,146,424 ($0.19 per share) in the same quarter last year [1]. - The total net realized and unrealized loss was $(1,784,553), or $(0.02) per share, contrasting with a gain of $9,886,429 ($0.11 per share) in the previous quarter and a loss of $(8,683,161) ($(0.10) per share) in the same quarter last year [1].

NEW YORK, Feb. 27, 2026 /PRNewswire/ -- AllianceBernstein Global High Income Fund, Inc. (NYSE:AWF), a registered closed‑end investment company, today announced earnings for the third quarter ended December 31, 2025.Total net assets of the Fund on December 31, 2025 were $985,227,126 as compared with $993,104,684 on September 30, 2025 and $978,431,163 on December 31, 2024. On December 31, 2025, the net asset value per share was $11.43 based on 86,229,677 shares of common stock outstanding.For the period Octob ...

Olema Pharmaceuticals Inc. (NASDAQ:OLMA) is one of 15 stocks with the biggest hedge fund momentum, after gaining 28 hedge fund holders during the fourth quarter of 2025. On February 19, Citi analyst Yigal Nochomovitz maintained a Buy rating on Olema Pharmaceuticals Inc. (NASDAQ:OLMA) and set a price target of $60. Meanwhile, on February 11, Stifel initiated coverage of Olema Pharmaceuticals Inc. (NASDAQ:OLMA) with a Buy rating and $48 price target, saying that it conservatively modeled peak sales estimates ...